Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic
暂无分享,去创建一个
I. Holme | A. Semb | T. Kvien | T. Pedersen | S. Rollefstad | A. S. Eirheim
[1] I. Holme,et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. , 2012, Arthritis and rheumatism.
[2] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[3] J. Olesen,et al. Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study , 2012, Annals of the rheumatic diseases.
[4] T. MacDonald,et al. Effectiveness of Statins on Total Cholesterol and Cardiovascular Disease and All-cause Mortality in Osteoarthritis and Rheumatoid Arthritis , 2012, The Journal of Rheumatology.
[5] D. O'leary,et al. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. , 2011, Arthritis and rheumatism.
[6] A. Wagih,et al. Effect of Atorvastatin on Inflammation and Modification of Vascular Risk Factors in Rheumatoid Arthritis , 2011, The Journal of Rheumatology.
[7] D. Veale,et al. Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis , 2010, The Journal of Rheumatology.
[8] I. Holme,et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study , 2010, Annals of the rheumatic diseases.
[9] J. Kastelein,et al. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins , 2010, Nature Reviews Rheumatology.
[10] B. Dijkmans,et al. Signs of Accelerated Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis , 2010, The Journal of Rheumatology.
[11] D. Symmons,et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? , 2009, Annals of the rheumatic diseases.
[12] Javier Martín,et al. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. , 2009, Seminars in arthritis and rheumatism.
[13] K. Kotseva,et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries , 2009, The Lancet.
[14] Mohsen Sadatsafavi,et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. , 2008, Arthritis and rheumatism.
[15] D. Scott,et al. An audit of recording cardiovascular risk factors in patients with rheumatoid arthritis and systemic lupus erythematosus in centres in East Anglia and the South East. , 2008, Rheumatology.
[16] I. Wilkinson,et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. , 2007, Journal of the American College of Cardiology.
[17] H. Paulus,et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. , 2007, The Journal of rheumatology.
[18] M. Bala,et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. , 2006, The Journal of rheumatology.
[19] Marie Gerhard-Herman,et al. Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. , 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[20] B. Dijkmans,et al. Statin therapy might be beneficial for patients with ankylosing spondylitis , 2005, Annals of the rheumatic diseases.
[21] Stephen W. Gutkin,et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study , 2005, Current medical research and opinion.
[22] B. Dijkmans,et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. , 2004, Seminars in arthritis and rheumatism.
[23] G. McColl,et al. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.
[24] R. Madhok,et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial , 2004, The Lancet.
[25] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[26] J. Manson,et al. Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis , 2003, Circulation.
[27] G. McColl,et al. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? , 2002, Arthritis and rheumatism.
[28] A. V. van Gammeren,et al. Analytical performance evaluation of the Cobas 6000 analyzer – special emphasis on trueness verification , 2008, Clinical chemistry and laboratory medicine.
[29] J. Olesen,et al. Extended Report , 2022 .